Jorge Luis Poo
Overview
Explore the profile of Jorge Luis Poo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Poo J, Torre A, Aguilar-Ramirez J, Cruz M, Mejia-Cuan L, Cerda E, et al.
Hepatol Int
. 2020 Aug;
14(5):817-827.
PMID: 32813194
Background And Aims: Pirfenidone (PFD), an oral antifibrotic drug, has been authorized by the EMA and FDA for treatment of idiopathic pulmonary fibrosis. Few studies have addressed its use in...
2.
Galan-Herrera J, Poo J, Rosales-Sanchez O, Fuentes-Fuentes E, Carino L, Burke-Fraga V, et al.
Clin Ther
. 2009 Oct;
31(8):1796-803.
PMID: 19808138
Background: Levofloxacin is a synthetic fluoroquinolone with a broad spectrum of antibacterial activity. It is indicated for the treatment of respiratory, sinus, skin, and urinary tract infections. Although generic formulations...
3.
Galan-Herrera J, Poo J, Maya-Barrios J, de Lago A, Oliva I, la Parra M, et al.
Clin Ther
. 2008 Oct;
30(9):1667-74.
PMID: 18840372
Background: Ketorolac tromethamine (ie, ketorolac) is an NSAID that appears to have several mechanisms of action, including inhibition of prostaglandin synthesis, modulatory effect on opioid receptors, and nitric oxide synthesis....
4.
Poo J, Galan J, Rosete A, de Lago A, Oliva I, la Parra M, et al.
Clin Ther
. 2008 May;
30(4):693-9.
PMID: 18498918
Background: Omeprazole is a proton-pump inhibitor that acts to reduce acid secretion in the stomach and is used for treating various acid-related gastrointestinal disorders. There are several generic formulations of...
5.
Poo J, Gongora J, Sanchez-Avila F, Aguilar-Castillo S, Garcia-Ramos G, Fernandez-Zertuche M, et al.
Ann Hepatol
. 2006 Dec;
5(4):281-8.
PMID: 17151582
Despite steady progress in therapeutics of liver disease, portal systemic encephalopathy remains to be a great challenge for clinicians because of the heterogeneity of neuropsychiatric symptoms, multiple risk factors and...
6.
Lizardi-Cervera J, Poo J, Romero-Mora K, Castaneda B, Pichardo-Bahena R, Moran S, et al.
Ann Hepatol
. 2006 Dec;
5(4):257-62.
PMID: 17151577
The role of hepatitis C virus (HCV) is well established in the development of chronic hepatitis, cirrhosis and hepatic carcinoma, as well as in mixed type II cryoglobulinemia, membranoproliferative glomerulonephritis(MPGN)...
7.
Poo J, Gongora J
Ann Hepatol
. 2006 Oct;
5(3):224-6.
PMID: 17060889
Hepatic perforation is an unusual complication of woman pregnancy associated with a poor outcome. A comprehensive review of epidemiology, clinical spectrum, diagnostic methods and therapeutic options is presented in this...
8.
Lizardi-Cervera J, Soto Ramirez L, Poo J, Uribe M
Ann Hepatol
. 2005 Sep;
4(3):188-91.
PMID: 16177658
Objective: To evaluate the frequency of hepatobiliary diseases and the clinical manifestations in patients with HIV treated with non highly active anti-retroviral therapy. Methods: Seven hundred clinical records of patients...
9.
Poo J, Sanchez-Avila F, Kershenobich D, Garcia-Samper X, Gongora J, Uribe M
J Gastroenterol Hepatol
. 2005 Jan;
19(12):S79-81.
PMID: 15641210
Despite steady progress in antiviral treatment for patients with chronic hepatitis C virus(HCV), many patients still have detectable serum HCV RNA levels by the end of interferon-based treatment and are...
10.
Poo J, Sanchez-Avila F, Kershenobich D, Garcia-Samper X, Gongora J, Uribe M
J Gastroenterol Hepatol
. 2004 Nov;
19 Suppl 6:S79-81.
PMID: 15546256
Despite steady progress in antiviral treatment for patients with chronic hepatitis C virus (HCV), many patients still have detectable serum HCV RNA levels by the end of interferon-based treatment and...